In addition to its anti‐aging effect, KDM1A inhibitor IMG‐7289 has been clinically investigated for treatment of solid and hematologic malignancies (NCT02842827, NCT05191797), while preclinical studies have demonstrated its role in the regulation of stemness in different myeloid and solid cancers (Karakaidos et al., 2019), supporting the status of KDM1A as a promising dual‐purpose target candidate for anti‐aging and anti‐cancer treatment. Here, KDM1A is linked to hematologic disorder.